BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gu L, Li H, Wang H, Ma X, Wang L, Chen L, Zhao W, Zhang Y, Zhang X. Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma. J Cancer Res Clin Oncol 2017;143:499-508. [DOI: 10.1007/s00432-016-2304-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 xing Z, Chen Y, Cai G, Chen S. Clinical characteristic and survival analysis of distant metastatic sarcomatoid renal cell carcinoma: A study of 378 patients.. [DOI: 10.21203/rs.3.rs-1567322/v2] [Reference Citation Analysis]
2 Zhi H, Feng M, Liu S, Na T, Zhang N, BiLiGe W. Prognostic Significance of Sarcomatoid Differentiation in Patients With Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Front Oncol 2020;10:591001. [PMID: 33134181 DOI: 10.3389/fonc.2020.591001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Blum KA, Gupta S, Tickoo SK, Chan TA, Russo P, Motzer RJ, Karam JA, Hakimi AA. Sarcomatoid renal cell carcinoma: biology, natural history and management. Nat Rev Urol 2020;17:659-78. [PMID: 33051619 DOI: 10.1038/s41585-020-00382-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
4 Shapiro DD, Westerman ME, Karam JA, Wood CG. Cytoreductive Nephrectomy in Patients Presenting With Advanced Disease: Have We Finally Answered the Question? Cancer J 2020;26:382-9. [PMID: 32947306 DOI: 10.1097/PPO.0000000000000470] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Yang B, Xia H, Xu C, Lu M, Zhang S, Wang G, Ma L. Impact of sarcomatoid differentiation and rhabdoid differentiation on prognosis for renal cell carcinoma with vena caval tumour thrombus treated surgically. BMC Urol 2020;20:14. [PMID: 32070319 DOI: 10.1186/s12894-020-0584-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
6 Pecoraro A, Palumbo C, Knipper S, Rosiello G, Luzzago S, Tian Z, Shariat SF, Saad F, Lavallée L, Briganti A, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. Clin Genitourin Cancer 2020;18:e610-8. [PMID: 32173357 DOI: 10.1016/j.clgc.2020.02.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 DiNatale RG, Xie W, Becerra MF, Silagy AW, Attalla K, Sanchez A, Mano R, Marcon J, Blum KA, Benfante NE, Voss MH, Motzer RJ, Coleman J, Choueiri TK, Reznik E, Russo P, Heng DYC, Hakimi AA. The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. Eur Urol Oncol 2020;3:47-56. [PMID: 31735646 DOI: 10.1016/j.euo.2019.10.002] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
8 Silagy AW, Mano R, Blum KA, DiNatale RG, Marcon J, Tickoo SK, Reznik E, Coleman JA, Russo P, Hakimi AA. The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology 2020;136:169-75. [PMID: 31726184 DOI: 10.1016/j.urology.2019.08.058] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
9 Shapiro DD, Abel EJ. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors. Current Opinion in Urology 2019;29:513-20. [DOI: 10.1097/mou.0000000000000658] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Alevizakos M, Gaitanidis A, Nasioudis D, Msaouel P, Appleman LJ. Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clin Genitourin Cancer 2019;17:e447-53. [PMID: 30799129 DOI: 10.1016/j.clgc.2019.01.005] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
11 Bhindi B, Abel EJ, Albiges L, Bensalah K, Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T, Bex A. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. European Urology 2019;75:111-28. [DOI: 10.1016/j.eururo.2018.09.016] [Cited by in Crossref: 94] [Cited by in F6Publishing: 106] [Article Influence: 23.5] [Reference Citation Analysis]
12 Mason RJ, Wood L, Kapoor A, Basappa N, Bjarnason G, Boorjian SA, Breau RH, Cagiannos I, Jewett MAS, Karakiewicz PI, Kassouf W, Kollmannsberger C, Lalani AA, Lattouf JB, Lavallée LT, Pautler S, Power N, Richard P, So A, Tanguay S, Rendon RA. Kidney Cancer Research Network of Canada (KCRNC) consensus statement on the role of cytoreductive nephrectomy for patients with metastatic renal cell carcinoma. Can Urol Assoc J 2019;13:166-74. [PMID: 31199235 DOI: 10.5489/cuaj.5786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
13 D'Avella C, Abbosh P, Pal SK, Geynisman DM. Mutations in renal cell carcinoma. Urol Oncol 2020;38:763-73. [PMID: 30478013 DOI: 10.1016/j.urolonc.2018.10.027] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.8] [Reference Citation Analysis]
14 Zhang L, Zha Z, Qu W, Zhao H, Yuan J, Feng Y, Wu B. Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis. BMC Cancer 2018;18:870. [PMID: 30176824 DOI: 10.1186/s12885-018-4773-z] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
15 Zhang L, Wu B, Zha Z, Zhao H, Feng Y. The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis. Cancer Manag Res 2018;10:1687-703. [PMID: 29970967 DOI: 10.2147/CMAR.S166710] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
16 Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
17 Lee CH, Kesari V, Legesse T, Chen W. FDG PET/CT of Chromophobe Renal Cell Carcinoma With Sarcomatoid Differentiation. Clin Nucl Med 2018;43:367-9. [PMID: 29485439 DOI: 10.1097/RLU.0000000000002031] [Reference Citation Analysis]
18 Edelson MP, Wu WJ, Kurzyna A, Steckel J. Rapid recurrence and radiographic progression of sarcomatoid renal cell carcinoma. Urol Case Rep 2018;16:6-8. [PMID: 29034177 DOI: 10.1016/j.eucr.2017.09.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]